HRPC(SH:600829)2015-10-23 16:00Financial Performance - Net profit attributable to shareholders decreased by 15.84% to CNY 137,433,748.24 for the first nine months of the year[7]. - Operating revenue for the first nine months was CNY 6,787,359,739.89, a slight decrease of 0.25% compared to the same period last year[7]. - Basic and diluted earnings per share decreased by 15.84% to CNY 0.2370[8]. - Total profit for the first nine months of 2015 was CNY 190,108,780.99, down 8.8% from CNY 208,567,772.69 in the same period last year[33]. - The company’s net profit for the first nine months of 2015 was CNY 131,060,261.05, down 12.6% from CNY 149,965,192.93 in the same period last year[33]. - The company reported a decrease in total operating revenue for the first nine months of 2015 to CNY 6,787,359,739.89, a slight decline of 0.25% from CNY 6,804,391,847.36 in the previous year[31]. - The company experienced a significant increase in operating costs, with the cost of goods sold rising to CNY 5,983,183,182.90 for the first nine months of 2015, up 7.3% from CNY 5,573,765,892.83 in the previous year[32]. Cash Flow - Net cash flow from operating activities decreased by 68.33% to CNY 173,612,673.70 for the first nine months[7]. - Cash flow from operating activities decreased by 68.33% to CNY 173,612,673.70 from CNY 548,195,661.40 in the previous year[17]. - The company reported a total cash inflow from operating activities of approximately ¥5.62 billion for the first nine months of 2015, compared to ¥6.92 billion in the same period last year[40]. - Operating cash inflow for the year-to-date period (January to September) was $187.89 million, a decrease from $1.23 billion in the same period last year[43]. - Net cash flow from operating activities was -$73.16 million, compared to $554.36 million in the previous year[43]. - Total cash inflow from operating activities was impacted by a decrease in cash received from sales, which was $178.94 million compared to $1.19 billion last year[43]. Assets and Liabilities - Total assets decreased by 40.94% to CNY 4,051,383,940.42 compared to the end of the previous year[7]. - The company has a total asset of CNY 4,051,383,940.42 as of September 30, 2015, down from CNY 6,859,901,211.58 at the beginning of the year, a decrease of approximately 41%[26]. - Total current assets decreased from CNY 5,187,002,832.54 at the beginning of the year to CNY 3,503,041,129.13, a decline of approximately 32.4%[24]. - Total liabilities decreased from CNY 3,873,117,984.38 to CNY 2,629,599,866.25, a decline of about 32.1%[26]. - Total equity attributable to shareholders decreased from CNY 2,926,569,537.57 to CNY 1,421,784,074.17, a drop of approximately 51.5%[26]. - Non-current assets decreased from CNY 1,672,898,379.04 to CNY 548,342,811.29, a decline of about 67.2%[25]. Shareholder Information - The total number of shareholders at the end of the reporting period was 24,278[12]. - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., held 74.82% of the shares[12]. Government Support and Other Income - The company received government subsidies amounting to CNY 4,422,079.23 during the first nine months[10]. - Non-recurring gains and losses for the first nine months totaled CNY 4,431,166.91[10]. Restructuring and Competition - The company completed a major asset restructuring in April 2015, leading to a clearer business positioning between the company and its controlling shareholder[19]. - The restructuring resolved the issue of competition between the company and its controlling shareholder, allowing both to focus on their respective business platforms[20]. Inventory and Receivables - Accounts receivable increased by 20.53% from CNY 1,726,719,388.84 to CNY 2,081,158,433.92, attributed to increased sales revenue in the pharmaceutical business[15]. - Inventory decreased significantly from CNY 1,638,418,093.94 to CNY 802,089,088.72, a reduction of approximately 51%[24].